Table 3. Proportion of subjects reporting changes in hematologic parameters1.
| Regimens containing interferon | Regimens free of interferon | ||||
| Hematologic parameter |
Placebo (12 weeks) (n = 71) |
Sofosbuvir plus ribavirina (12 weeks) (n = 647) |
Sofosbuvir plus ribavirina (24 weeks) (n = 250) |
Peginterferon alfa plus ribavirinb (24 weeks) (n = 242) |
Sofosbuvir plus peginterferon alfa and ribavirin (12 weeks) (n = 327) |
| Hemoglobin | |||||
| < 10 g/dL | 0% | 8% | 6% | 14% | 23% |
| < 8.5 g/dL | 0% | 1% | < 1% | 2% | 2% |
| Neutrophils | |||||
| ≥ 0.5 to < 0.75 × 109/L | 1% | < 1% | 0% | 12% | 15% |
| < 0.5 × 109/L | 0% | < 1% | 0% | 2% | 5% |
| Platelets | |||||
| ≥ 25 to < 50 × 109/L | 3% | < 1% | 1% | 7% | < 1% |
| < 25 × 109/L | 0% | 0% | 0% | 0% | 0% |
a
Patients received weight-based ribavirin dosing.
b
Patients received ribavirin 800 mg regardless of weight.